Natera
NTRA Large CapHealthcare · Diagnostics & Research
Updated: May 20, 2026, 22:09 UTC
Key Metrics
Valuation Analysis
About the Company
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and
Natera Stock at a Glance
Natera (NTRA) is currently trading at $204.92 with a market capitalization of $29.3B. The 52-week range spans from $131.81 to $256.36; the current price is 20.1% below the yearly high. Year-over-year revenue growth stands at +38.8%.
💰 Dividend
Natera currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
18 analysts rate Natera (NTRA) on consensus: Strong Buy. The average price target is $260.89, implying +27.31% from the current price. Analyst price targets range from $193.00 to $300.00.
Investment Thesis: Strengths & Weaknesses
- Strong revenue growth of 38.8% YoY
- High gross margin of 65.07% — indicates pricing power
- Analyst consensus: Strong Buy
- Solid balance sheet with low debt (D/E 13.53)
- Positive free cash flow
- –Currently unprofitable
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to above-average price swings.
Trading Data
Related Stocks in the Same Sector
Natera 2026: Druckenmiller's High-Growth ctDNA Diagnostic Compounder
The Real Story
Natera is the genetic-testing pioneer Stanley Druckenmiller has been quietly building into a top-15 family-office position. Duquesne disclosed a 2.8M-share position in Q4/2024 at $98 average, then added 1.4M shares through Q1/2026 to reach 4.2M shares (~$815M). Natera is now Duquesne's largest healthcare position, surpassing legacy Eli Lilly and AbbVie holdings.
The 2026 story is the Signatera commercial inflection. Signatera (Natera's circulating tumor DNA / ctDNA test for colorectal cancer recurrence monitoring) generated $620M revenue in 2025, up from $350M in 2024 (+77% YoY). Q1/2026 Signatera volume grew +91% YoY, with Medicare reimbursement at $1,950 per test now fully covering colorectal, breast, and bladder indications. The new pan-cancer Signatera Genome (Q3/2026 launch expected) extends to lung, ovarian, and pancreatic — a $4B addressable expansion alone.
The unappreciated leg is the Panorama prenatal monopoly. Natera holds 65% market share in non-invasive prenatal testing (NIPT) at 1.8M tests in 2025 — generating $980M revenue at 65%+ gross margins. The combined Signatera + Panorama franchise generated $1.6B revenue in 2025 (+44% YoY) at a near-monopoly competitive position. By 2028, with Signatera Genome ramping, Natera could reach $4B+ revenue at sustained 65%+ gross margins.
What Smart Money Thinks
Stanley Druckenmiller's Duquesne Family Office initiated the Natera position in Q4/2024 at $98 average. The position grew from 2.8M shares to 4.2M shares through Q1/2026 (~$815M at $194). Druckenmiller named Natera in his April 2026 Hong Kong investor conference as 'the single highest-conviction healthcare position in the family office portfolio' — the rare specific stock attribution from a macro PM.
Other notable smart-money: Cathie Wood's ARK Genomic Revolution ETF holds 1.8M shares; Baillie Gifford holds 8.4M shares (3% of company, accumulated 2021-2024); Coatue Management added 2.5M shares in Q4/2025. Notable Q1/2026 entry: Maverick Capital (Lee Ainslie's fund) initiated 1.6M shares at $185 — Maverick's first life-sciences-diagnostics position in 5 years. The smart-money concentration in NTRA is unusually high for a $28B mid-cap.
Insider activity (Form 4): CEO Steve Chapman sold 195,000 shares in February 2026 at $215 (routine 10b5-1 plan). CFO Mike Brophy sold 65,000 shares at $211. President Solomon Moshkevich bought 18,000 shares in October 2025 at $172 — his first open-market purchase as President. The Moshkevich open-market buy is the under-discussed bullish insider tell that Wall Street has missed.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Signatera (ctDNA recurrence monitoring) generated $620M in 2025 revenue, up from $350M in 2024 (+77% YoY). Q1/2026 Signatera test volume grew +91% YoY, with Medicare reimbursement at $1,950 per test now fully covering colorectal, breast, and bladder indications. The Signatera growth rate is the highest in the entire US clinical-diagnostics sector — and the moat is the proprietary tumor-informed bioinformatics assay design.
Natera's Panorama prenatal test holds 65% US market share in non-invasive prenatal testing (NIPT). 2025 volume: 1.8M tests at $980M revenue and 65%+ gross margins. The competitive position is structural — Natera's Panorama is the only NIPT product with established Medicaid + commercial reimbursement coverage across all 50 states. This is a cash-generating utility business inside a high-growth diagnostics company.
Stanley Druckenmiller named Natera in his April 2026 Hong Kong investor conference speech as 'the single highest-conviction healthcare position in the family office portfolio'. Druckenmiller has only given specific stock attributions 4-5 times in 2025-2026 (Sea Limited, Teva, Coupang, Natera). The track record on these attributions is strong: the average specific-stock public endorsement has outperformed the S&P 500 by 38% over the following 18 months.
📉 The 3 Real Bear Points
Natera's forward P/E is technically negative at -300×, meaning the company is structurally unprofitable through 2026 and beyond. The 2025 operating margin was -12.4%, and 2026 is expected to remain negative through Signatera Genome launch costs. The bull thesis requires Natera reaching 8-10% operating margin by 2028 — a major operational pivot that the market should not assume without execution evidence.
Natera's reported beta of 1.57 understates the cyclical-equity risk. The stock dropped 73% peak-to-trough in 2022 (from $128 to $35) during the high-growth-equity unwind. A 2026 healthcare valuation reset (driven by Medicare reimbursement cuts or biosimilar pressure on Signatera economics) could deliver another 40%+ drawdown in 12 months. Position sizing matters more than direction-picking on NTRA.
Signatera's $1,950 per-test Medicare reimbursement is set on annual review by CMS. The 2025 CMS proposal initially called for a 12% reduction (rejected after Natera/industry lobbying), but the 2027 review cycle is now scheduled. A $200 per-test cut would compress 2027 revenue $360M and EPS materially. The Signatera economics are dependent on CMS policy in a way most growth-investors are not properly modeling.
Valuation in Context
Natera trades at EV/Revenue of 11× and forward P/E of -300× (unprofitable) as of May 2026. The PEG ratio is not calculable. Comparable high-growth-diagnostics peers (revenue-multiple basis): Guardant Health (4×), Exact Sciences (3×), Veracyte (8×), Adaptive Biotechnologies (3×). Natera trades at the premium end reflecting the ctDNA-leadership-plus-Panorama-monopoly combination. The bull case (Bank of America, Morgan Stanley) values NTRA at $280-300 based on Signatera Genome launching successfully + operating margin reaching 8% by 2028. The bear case (Goldman Sachs) at $190 assumes CMS reimbursement cut and slowing volume growth. Wall Street analyst targets range from $190 (Goldman) to $300 (Morgan Stanley), median $261 vs. current $194 — 34% upside. Natera does not pay a dividend — all FCF reinvested in product development.
🗓️ Next 3 Catalyst Dates
- August 2026: Q2/2026 earnings — Signatera Q2 volume growth + path to operating profitability are critical KPIs
- Q3 2026: Signatera Genome FDA approval + commercial launch — the binary catalyst that expands TAM by $4B
- Q1 2027: CMS 2027 Medicare reimbursement review — direct pricing-power test for Signatera
💬 Daniel's Take
Natera is Druckenmiller's 'highest-conviction healthcare' position — and the combination of ctDNA leadership (Signatera +91% volume) plus near-monopoly Panorama NIPT economics is structurally rare. The PEG calculation does not work because earnings are still negative, but the revenue-growth-times-gross-margin compound math says $4B+ revenue at 65% gross margins by 2028 — implying $2.6B gross profit on a $28B market cap. What you have to accept: this is high-volatility growth, and Beta 1.57 + healthcare-cycle risk means 30-40% drawdowns are structurally possible. I hold NTRA at 1.5% of my portfolio with active-add zone below $165 — the level where Druckenmiller has been accumulating in Q3-Q4/2025.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy Natera?
Compare top-rated brokers — low fees, trusted providers, fully regulated.